Initial Statement of Beneficial Ownership (3)
April 07 2020 - 06:12PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP
OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
1. Name
and Address of Reporting Person * Abbhi
Sankesh |
2. Date of Event Requiring Statement
(MM/DD/YYYY)
3/30/2020
|
3. Issuer Name and Ticker or Trading
Symbol BRAINSTORM CELL THERAPEUTICS INC. [BCLI] |
(Last)
(First)
(Middle)
C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF
AMERICAS, 28TH FLOOR |
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)__X__
Director _____
10% Owner
_____ Officer (give title
below) _____
Other (specify below)
|
(Street)
NEW
YORK, NY 10019
(City)
(State)
(Zip)
|
5. If Amendment, Date Original
Filed(MM/DD/YYYY)
|
6. Individual or Joint/Group
Filing(Check Applicable
Line)_X_ Form filed by One Reporting
Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially
Owned
|
1.Title of Security
(Instr. 4) |
2. Amount of Securities Beneficially Owned
(Instr. 4) |
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) |
4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Common Stock |
2117751 |
I |
Abbhi Investments, LLC (1) |
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 4) |
2. Date Exercisable and Expiration Date
(MM/DD/YYYY) |
3. Title and Amount of Securities Underlying
Derivative Security
(Instr. 4) |
4. Conversion or Exercise Price of Derivative
Security |
5. Ownership Form of Derivative Security: Direct (D)
or Indirect (I)
(Instr. 5) |
6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Warrant to Purchase Common Stock |
3/6/2020 |
3/6/2023 |
Common Stock |
250000 (2) |
$15.00 |
I |
Abbhi Investments, LLC (1) |
Explanation of
Responses: |
(1) |
Abbhi Investments, LLC is
the record owner of these securities. Mr. Sankesh Abbhi is the
manager of Abbhi Investments, LLC and maintains sole voting and
investment power with respect to common stock and warrants held by
Abbhi Investments, LLC. |
(2) |
Pursuant to the March 6,
2020 Securities Purchase Agreement between Abbhi Investments, LLC
and the Issuer, for an aggregate purchase price of $10,000,000,
Abbhi Investments, LLC received 1,250,000 shares of Common Stock
and a Warrant for 250,000 shares of Common Stock with a purchase
price per share of $15.00 and an expiration date of the third
anniversary of the date of issuance. |
Reporting
Owners
|
Reporting Owner Name / Address |
Relationships
|
Director |
10% Owner |
Officer |
Other |
Abbhi Sankesh
C/O BRAINSTORM CELL THERAPEUTICS INC.
1325 AVENUE OF AMERICAS, 28TH FLOOR
NEW YORK, NY 10019 |
X |
|
|
|
Signatures
|
/s/ Nathaniel Gaede (Pursuant to Power of
Attorney) |
|
4/7/2020 |
**Signature
of Reporting Person |
Date |